• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Comprehensive Overview of 1-Cyclobutyl-1H-indazole-3-carboxylic acid (CAS No. 921941-16-4): Properties, Applications, and Research Insights

1-Cyclobutyl-1H-indazole-3-carboxylic acid (CAS No. 921941-16-4) is a specialized heterocyclic compound gaining traction in pharmaceutical and agrochemical research due to its unique structural features. As a derivative of indazole carboxylic acid, this molecule combines a cyclobutyl ring with an indazole core, offering distinct reactivity and binding properties. Researchers are increasingly exploring its potential as a building block for drug discovery, particularly in targeting protein-protein interactions and enzyme modulation.

The compound's molecular formula (C₁₂H₁₂N₂O₂) and molecular weight (216.24 g/mol) make it suitable for small-molecule therapeutic development. Recent studies highlight its relevance in designing kinase inhibitors, with particular interest in its hydrogen bond donor/acceptor capacity. The carboxylic acid moiety provides versatility for further derivatization, enabling the creation of amides, esters, and other pharmacologically active derivatives.

In synthetic chemistry, 1-Cyclobutyl-1H-indazole-3-carboxylic acid serves as a valuable intermediate for constructing more complex heterocyclic systems. Its indazole scaffold is recognized for mimicking purine bases, making it relevant in nucleic acid-targeting therapies. The cyclobutyl group introduces steric constraints that can enhance selectivity in biological interactions, a feature increasingly sought after in fragment-based drug design approaches.

From a physicochemical property perspective, this compound typically appears as a white to off-white crystalline powder with moderate solubility in polar organic solvents. Its logP value (predicted around 2.1) suggests favorable membrane permeability, while the carboxylic acid group ensures sufficient aqueous solubility for biological testing. These balanced properties contribute to its growing popularity in medicinal chemistry optimization programs.

Current research trends focus on leveraging 1-Cyclobutyl-1H-indazole-3-carboxylic acid in cancer therapeutics, particularly as a component of targeted therapy agents. The compound's ability to participate in hydrogen bonding networks makes it valuable for disrupting protein-protein interactions involved in tumor progression. Additionally, its structural features align with emerging interests in allosteric modulator development for neurological disorders.

Quality control of CAS No. 921941-16-4 typically involves HPLC purity assessment (>98%) and thorough characterization by NMR spectroscopy and mass spectrometry. The synthetic route often begins with indazole-3-carboxylic acid derivatives, followed by N-cyclobutylation under optimized conditions. Process chemists emphasize the importance of controlling regioselectivity during the cyclobutyl introduction to ensure product consistency.

In the context of green chemistry initiatives, recent improvements in the synthesis of 1-Cyclobutyl-1H-indazole-3-carboxylic acid have focused on reducing organic solvent use and implementing catalytic methods for the key cyclobutylation step. These advancements address growing industry demands for sustainable synthetic approaches while maintaining high yields and purity.

The compound's stability profile shows compatibility with standard pharmaceutical formulation conditions, though the carboxylic acid group may require protection during certain synthetic transformations. Proper storage typically recommends protection from moisture at controlled room temperature, with stability maintained for extended periods when handled appropriately.

Emerging applications explore 1-Cyclobutyl-1H-indazole-3-carboxylic acid in material science, particularly as a component of metal-organic frameworks (MOFs) and coordination polymers. The rigid indazole structure combined with the cyclobutyl conformation offers unique geometric constraints valuable for designing functional materials with specific porosity or catalytic properties.

From a regulatory perspective, this compound currently falls under general chemical handling guidelines without special restrictions. However, researchers should consult updated chemical safety databases as regulatory landscapes evolve. The growing interest in indazole derivatives across multiple industries suggests increasing importance for this chemical class in coming years.

For researchers sourcing CAS 921941-16-4, key considerations include batch-to-batch consistency, comprehensive analytical documentation, and supplier reliability. The compound's pricing reflects its status as a specialty chemical, with costs varying based on purity specifications and order scale. Many contract research organizations now include this building block in their custom synthesis portfolios.

Future directions for 1-Cyclobutyl-1H-indazole-3-carboxylic acid research may explore its potential in proteolysis targeting chimeras (PROTACs) and other targeted protein degradation platforms. The molecule's balanced properties and derivatization potential position it well for these cutting-edge therapeutic approaches that are transforming drug discovery paradigms.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)